110 related articles for article (PubMed ID: 29858225)
1.
Strickler JH
Cancer Discov; 2018 Jun; 8(6):679-681. PubMed ID: 29858225
[TBL] [Abstract][Full Text] [Related]
2. Optimized EGFR Blockade Strategies in
Corso S; Pietrantonio F; Apicella M; Migliore C; Conticelli D; Petrelli A; D'Errico L; Durando S; Moya-Rull D; Bellomo SE; Ughetto S; Degiuli M; Reddavid R; Fumagalli U; De Pascale S; Sgroi G; Rausa E; Baiocchi GL; Molfino S; De Manzoni G; Bencivenga M; Siena S; Sartore-Bianchi A; Morano F; Corallo S; Prisciandaro M; Di Bartolomeo M; Gloghini A; Marsoni S; Sottile A; Sapino A; Marchiò C; Dahle-Smith A; Miedzybrodzka Z; Lee J; Ali SM; Ross JS; Alexander BM; Miller VA; Petty R; Schrock AB; Giordano S
Clin Cancer Res; 2021 Jun; 27(11):3126-3140. PubMed ID: 33542076
[TBL] [Abstract][Full Text] [Related]
3. Back from the Brink: EGFR Inhibition in Gastroesophageal Cancer.
Openshaw MR; Pinato DJ; Valeri N
Clin Cancer Res; 2021 Jun; 27(11):2964-2966. PubMed ID: 33771852
[TBL] [Abstract][Full Text] [Related]
4. Dual MET/EGFR therapy leads to complete response and resistance prevention in a MET-amplified gastroesophageal xenopatient cohort.
Apicella M; Migliore C; Capelôa T; Menegon S; Cargnelutti M; Degiuli M; Sapino A; Sottile A; Sarotto I; Casorzo L; Cassoni P; De Simone M; Comoglio PM; Marsoni S; Corso S; Giordano S
Oncogene; 2017 Mar; 36(9):1200-1210. PubMed ID: 27524418
[TBL] [Abstract][Full Text] [Related]
5. EGFR gene amplification is relatively common and associates with outcome in intestinal adenocarcinoma of the stomach, gastro-oesophageal junction and distal oesophagus.
Birkman EM; Ålgars A; Lintunen M; Ristamäki R; Sundström J; Carpén O
BMC Cancer; 2016 Jul; 16():406. PubMed ID: 27387915
[TBL] [Abstract][Full Text] [Related]
6. Perioperative chemotherapy with or without epidermal growth factor receptor blockade in unselected patients with locally advanced oesophagogastric adenocarcinoma: Randomized phase II study with advanced biomarker program of the German Cancer Society (AIO/CAO STO-0801).
Stahl M; Maderer A; Lordick F; Mihaljevic AL; Kanzler S; Hoehler T; Thuss-Patience P; Mönig S; Kunzmann V; Schroll S; Sandermann A; Tannapfel A; Meyer HJ; Schuhmacher C; Wilke H; Moehler M;
Eur J Cancer; 2018 Apr; 93():119-126. PubMed ID: 29501977
[TBL] [Abstract][Full Text] [Related]
7. Preexisting oncogenic events impact trastuzumab sensitivity in ERBB2-amplified gastroesophageal adenocarcinoma.
Kim J; Fox C; Peng S; Pusung M; Pectasides E; Matthee E; Hong YS; Do IG; Jang J; Thorner AR; Van Hummelen P; Rustgi AK; Wong KK; Zhou Z; Tang P; Kim KM; Lee J; Bass AJ
J Clin Invest; 2014 Dec; 124(12):5145-58. PubMed ID: 25401468
[TBL] [Abstract][Full Text] [Related]
8. Update on Gastroesophageal Adenocarcinoma Targeted Therapies.
Maron SB; Catenacci DVT
Hematol Oncol Clin North Am; 2017 Jun; 31(3):511-527. PubMed ID: 28501091
[TBL] [Abstract][Full Text] [Related]
9. Targeted therapy for advanced esophagogastric adenocarcinoma.
Kordes S; Cats A; Meijer SL; van Laarhoven HW
Crit Rev Oncol Hematol; 2014 Apr; 90(1):68-76. PubMed ID: 24183912
[TBL] [Abstract][Full Text] [Related]
10. Novel Targeted Therapies for Esophagogastric Cancer.
Maron SB; Catenacci DV
Surg Oncol Clin N Am; 2017 Apr; 26(2):293-312. PubMed ID: 28279470
[TBL] [Abstract][Full Text] [Related]
11. Epidermal Growth Factor Receptor Inhibition in the Management of Squamous Cell Carcinoma of the Lung.
Goss GD; Spaans JN
Oncologist; 2016 Feb; 21(2):205-13. PubMed ID: 26768483
[TBL] [Abstract][Full Text] [Related]
12. Chemotherapy and novel targeted therapies for operable esophageal and gastroesophageal junctional cancer.
van den Ende T; Smyth E; Hulshof MCCM; van Laarhoven HWM
Best Pract Res Clin Gastroenterol; 2018; 36-37():45-52. PubMed ID: 30551856
[TBL] [Abstract][Full Text] [Related]
13. Genomic Alterations and Targeted Therapy in Gastric and Esophageal Adenocarcinoma.
Pectasides E
Clin Ther; 2016 Jul; 38(7):1589-99. PubMed ID: 27041412
[TBL] [Abstract][Full Text] [Related]
14. Targeted therapies for advanced and metastatic adenocarcinoma of the gastroesophageal junction: is there something new?
Pasini F; Fraccon AP; Modena Y; Bencivenga M; Giacopuzzi S; La Russa F; Gusella M; de Manzoni G
Gastric Cancer; 2017 Jan; 20(1):31-42. PubMed ID: 27568322
[TBL] [Abstract][Full Text] [Related]
15. ctDNA in Gastric and Gastroesophageal Cancer: Prognostic, Predictive, or Preliminary?
Frankell AM; Smyth EC
Clin Cancer Res; 2019 Dec; 25(23):6893-6895. PubMed ID: 31582518
[TBL] [Abstract][Full Text] [Related]
16. Biomarker-driven targeted therapies for gastric/gastro-esophageal junction malignancies.
Kim S; Barzi A; Rajdev L
Semin Oncol; 2018 Jun; 45(3):133-150. PubMed ID: 30262395
[TBL] [Abstract][Full Text] [Related]
17. Monitoring of cyclooxygenase-2 levels can predict EGFR mutations and the efficacy of EGFR-TKI in patients with lung adenocarcinoma.
Li H; Wang Y; Su F; Li J; Gong P
Int J Clin Exp Pathol; 2015; 8(5):5577-83. PubMed ID: 26191267
[TBL] [Abstract][Full Text] [Related]
18. Therapeutic Strategies in Diseases of the Digestive Tract - 2015 and Beyond Targeted Therapies in Colon Cancer Today and Tomorrow.
Pohl M; Schmiegel W
Dig Dis; 2016; 34(5):574-9. PubMed ID: 27332557
[TBL] [Abstract][Full Text] [Related]
19. A Randomized Phase II Study of FOLFOX With or Without the MET Inhibitor Onartuzumab in Advanced Adenocarcinoma of the Stomach and Gastroesophageal Junction.
Shah MA; Cho JY; Tan IB; Tebbutt NC; Yen CJ; Kang A; Shames DS; Bu L; Kang YK
Oncologist; 2016 Sep; 21(9):1085-90. PubMed ID: 27401892
[TBL] [Abstract][Full Text] [Related]
20. Fighting cancer drug resistance: Opportunities and challenges for mutation-specific EGFR inhibitors.
Juchum M; Günther M; Laufer SA
Drug Resist Updat; 2015 May; 20():12-28. PubMed ID: 26021435
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
